T1	Participants 132 148	healthy subjects
T2	Participants 851 862	healthy men
T3	Participants 872 1043	A randomized, placebo-controlled, dose-escalation trial with five cohorts (N7-GP dose of 12.5-100 Î¼g kg(-1) ) was performed. In each cohort, eight subjects were randomized
